頁籤選單縮合
題名 | 抗膽鹼藥物於膀胱過動症之治療=Anticholinergic Drugs for Treating Overactive Bladder |
---|---|
作者 | 羅兆智; 蔡慈貞; Lo, Chao-chih; Tsai, Tzu-cheng; |
期刊 | 藥學雜誌 |
出版日期 | 20130600 |
卷期 | 29:2=115 2013.06[民102.06] |
頁次 | 頁86-92 |
分類號 | 418.21 |
語文 | chi |
關鍵詞 | 膀胱過動症; 實證醫學; 抗膽鹼藥品; Overactive bladder; Anticholinergic drugs; |
中文摘要 | 膀胱過動症 (overactive bladder; OAB),是一種常見且影響生活品質的慢性疾病,病人經常為強烈而急促的尿意、伴隨著尿失禁等不便所困擾。主要的治療藥品以抗膽鹼藥品為主。本文透過系統性回顧及統合分析之實證文獻佐證,分析探討 oxybutynin、tolterodine、solifenacin、fesoterodine、trospium 等常見之抗膽鹼藥品,是否因膽鹼受體專一性、劑型差異 (立即釋放型、緩釋型等) 或給藥劑量、給藥方式之差異而影響其臨床療效及副作用之發生。緩釋劑型相較於立即釋放劑型提供更明確之療效與安全性的優勢,當使用較高劑量時則需考量伴隨副作用發生等潛在可能性。為了兼顧療效、安全性、耐受性等臨床考量重點,藉由實證醫學的深入分析探討,評析符合臨床療效與安全性要求之用藥建議。 |
英文摘要 | Overactive bladder (OAB) is a common chronic disease which interfere personal quality of life and result in a great impact. Patients often suffer from inconvenient urinary urgency and incontinence. Muscarinic receptor antagonists are the drug of mainstream therapy, such as oxybutynin, tolterodine, solifenacin, fesoterodine, and trospium. The therapeutic effects and side effects may depend on the specificity of cholinergic receptor, different formulation (immediate-released or extended released), dose, and route of administration of these agents. The purpose of this study is to investigate how these discrepancies influence the choice of treatment by systematic review and meta-analysis of randomized controlled trials. In contrast to immediate-release form, extended-release form provides more evidence of efficiency and safety. High dose regimen may accompany with potential side effects. If we concern these important clinical issues, such as efficiency, safety, and tolerability, further evaluation is necessary by evidence-based medicine and proposes a recommendation of the optimal drug therapy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。